Fig. 3From: FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extensionLong-term efficacy results from weeks 0 to 54 of treatment (to the end of Period II); a ACR20 response rate, b ACR50 response rate, c ACR70 response rate, d mean DAS28-CRP (95% CI). ACR American College of Rheumatology, CI confidence interval, DAS28-CRP disease activity score 28 based on C-reactive protein, RP reference productBack to article page